Alpha Tau Completes IMPACT Pancreatic Cancer Pilot Enrollment with 48 Patients

What happened

Alpha Tau Medical announced completion of patient enrollment in its multicenter IMPACT pilot study, which evaluates intratumoral Alpha DaRT combined with first-line chemotherapy for unresectable pancreatic cancer. Enrollment expanded from an initial 12 planned patients to 48 treated patients, driven by strong clinician and patient demand. The company attributes the expansion to favorable safety data from earlier Israeli and Canadian studies, and the study is intended to inform design of a planned pivotal trial. Data release is targeted for early 2027, and the IMPACT study anchors a global pancreatic program including ACAPELLA in France and a University of Verona study. While enrollment completion is a positive execution milestone, it remains a pilot study with efficacy data pending, and the company's near-term value still hinges on Japan commercialization and other 2026 readouts.

Implication

Investors should view this milestone as a modest positive that validates clinical demand and operational capability, but it does not alter the fundamental valuation drivers. The expanded enrollment from 12 to 48 patients suggests clinician enthusiasm and feasibility, yet safety and efficacy data will not be available until early 2027, leaving the pilot's impact on pivotal design and regulatory strategy unproven. Meanwhile, the company's near-term catalysts remain Japan PMS enrollment and the Q2 2026 GBM safety readout, which are more critical for near-term stock performance. The cash burn and lack of revenue mean continued reliance on capital markets, and the stock's valuation still embeds significant execution risk. Accordingly, we maintain our WAIT rating and $6.00 attractive entry, with no change to our price targets or trim levels based on this announcement.

Thesis delta

The investment thesis is unchanged: Alpha Tau remains a clinical-stage company with multiple shots on goal but no near-term revenue, and this enrollment completion is consistent with prior guidance but does not de-risk the key uncertainties around Japan commercialization and final clinical data. The pancreatic program adds optionality but its data readout in early 2027 is too distant to move near-term valuation. We continue to wait for Japan PMS enrollment traction and the GBM safety readout before reassessing.